9,672 results found

Cadwalader partner Leah Edelboim recently spoke with Bloomberg about the NAV market and the increased presence of insurers as lenders to private equity funds that want to borrow against their investments.

Partner Marc Elovitz discusses the SEC's ongoing enforcement priorities for private fund managers, examining heightened scrutiny of fees, expenses, and valuation processes. The conversation explores emerging compliance challenges across side letters, co-investments, continuation vehicles, and the expanding retail access to private markets.

Placement agent and PE investment bank Triago released its Private Equity Review & Outlook − Winter 2022-2023 this week, which includes a transcribed panel focused on non-dilutive financing...

Samsung Bioepis ("Samsung") announced on July 22 that the FDA approved its BLA for EPYSQLI, an eculizumab biosmilar referencing Alexion's SOLIRIS. EPYSQLI has been approved for the treatment of patients...

The constant cycle of acquisitions, affiliations and divestitures is continually reshaping the health care industry.

In this article, our partners discuss the increasing interest by private equity investors in physician practice management business models.

STADA and Sino Biopharmaceutical Limited have formed a strategic partnership to develop and commercialize biosimilar medications across Europe and neighboring regions. The collaboration focuses on bringing biosimilar alternatives to market, beginning with a pembrolizumab biosimilar targeting multiple cancer indications, with plans to expand into additional oncology and immunology treatments.

Reimbursement model changes and cost-cutting pressures imposed by the Patient Protection and Affordable Care Act, a lukewarm economy, and new regulatory challenges within healthcare continue to cause changes in private equity investment.

According to a BlackRock survey, 42% of insurance executives said they are likely to decrease their equity investments over the next 12 to 24 months, although the same number said they would maintain their equity exposure.

Partner Jordan Altman and counsel Jeewon Kim Serrato contributed to a Mergermarket report on data privacy considerations in M&A transactions.

Consumer spending and employment figures continue to show strength, but beneath these headline numbers lies a more complex reality. As household financial reserves steadily decline, questions emerge about the sustainability of current consumption patterns and what this divergence signals for economic stability ahead.

As restaurant operators continue to navigate a challenging environment, they face mounting pressure from declining consumer traffic, franchisee financial distress, value-focused pricing strategies, food safety concerns, and ongoing supply chain scrutiny.

On Mar. 9, 2015, the General Court confirmed the European Commission’s decision prohibiting the proposed merger between Deutsche Börse and NYSE Euronext. The merger—which would have brought together the two largest exchanges in the world for European financial derivatives— was blocked by the Commission in February 2012.

Reid Feldman chairs the 2017 European Private Target M&A Deal Points Study, a project of the Mergers and Acquisitions Market Trends Subcommittee, Mergers and Acquisitions Committee of the American Bar

There was significant antitrust activity in the third quarter of 2019. In the United States, the Federal Trade Commission (FTC) and Department of Justice (DOJ) continued an active docket

Antitrust regulators in the United States and Europe were very active in the final quarter of 2019. The FTC and DOJ continue to investigate and challenge M&A transactions

McDermott's Antitrust M&A Snapshot is a resource for in-house counsel and others who deal with antitrust M&A issues but are not faced with these issues on a daily basis.